Clinical Trial Update: PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung [Phase 2]

View source ↗

Summary

Phase 2 trial update on a combination of a PCSK9 inhibitor and a PD-1 inhibitor for metastatic non-small cell lung cancer that is refractory to prior anti-PD-1 …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• PCSK9 inhibitor (PCSK9 inhibitor)
• PD-1 inhibitor

Snippet

Sponsor: Duke University | Conditions: Non-small Cell Lung Cancer (NSCLC) | Phase 2 | Status: ACTIVE_NOT_RECRUITING